Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Andrew R. Robbins
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 258
- Beta
- 0.34
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 5.75
Financials
Revenue
$0.00-100.0%Net Income
$-111.43MEBITDA
$-109.61MFree Cash Flow
$-80.89MEPS (diluted)
$-0.59Shares Outstanding (diluted)
173.13M+1267.1%Operating Expenses
$117.18MCash & Debt
$791.13MRevenue by Segment (annual)
$25.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-328.94M | $-2.04 |
| 2024 | $0.00 | $-255.86M | $-2.32 |
| 2023 | $0.00 | $-192.41M | $-2.42 |
| 2022 | $0.00 | $-140.24M | $-2.26 |
| 2021 | $0.00 | $-72.27M | $-1.85 |
| 2020 | $7.87M | $-74.81M | $-6.00 |
| 2019 | $22.50M | $-30.27M | $-3.97 |
| 2018 | $9.73M | $-34.53M | $-5.55 |
| 2017 | $8.36M | $-25.49M | $-3.45 |
| 2016 | $6.36M | $-18.12M | $-3.10 |
| 2015 | $2.99M | $-6.59M | $-1.13 |
Valuation
COGThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-53.33%Social Signal Score
Mentions (15)
- Newsseekingalpha.com·5d ago·Positive
Cogent Biosciences, Inc. (COGT) Presents at UBS Global Biopharma Conference 2026 Transcript Cogent Biosciences, Inc. (COGT) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - News (RSS)investing·6d ago·Neutral
Cogent Biosciences stock hits 52-week low at 27.73 USD
View source ↗ - News (RSS)seekingalpha·15d ago·Positive
Cogent Communications Holdings, Inc. (CCOI) Q3 2026 Earnings Call Transcript
View source ↗ - 4chan /biz/biz·16d ago·Negative
CCOI is down 30% yesterday as they provide no clarity on refinancing their 700mm debt. It's being priced as if it's going bankrupt. Stock is down 95% in two years and 81% this year. However, David Schaeffer is a genius who is going to get that debt refinanced. He played hard before in the dot com crash, wiping out debt and buying bankrupt competitors. He got the Sprint network of T-Mobile for $1. He has a 10% stake in Cogent. He has a top tier loophole finding law firm and Evercore negotiatin
View source ↗ - 4chan /biz/biz·19d ago·Positive
>>62850961 Cogent WILL fix their debt issues and moon back up.
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Cogent Security Makes the Fortune Cyber 60 for a Second Year, With a Plan to Run Cyber Defense Like a Factory SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cogent Security, an applied AI cybersecurity company, reported that the PHP2Shell vulnerability exposed significant gaps in enterprise vulnerability response. Disclosed on October 21, PHP2Shell involved two critical flaws that had remained in PHP for more than a decade.
View source ↗ - News (RSS)investing·25d ago·Neutral
Moody’s cuts Cogent rating to Caa2 on mounting 2027 debt refinancing risks
View source ↗ - News (RSS)seekingalpha·40d ago·Neutral
Cogent Communications: When Debt Is A Real Issue
View source ↗ - Newsglobenewswire.com·68d ago·Negative
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM
View source ↗ - News (RSS)seekingalpha·74d ago·Positive
Cogent Communications Holdings, Inc. (CCOI) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript
View source ↗ - News (RSS)hellenicshipping·77d ago·Negative
Cosco readies for growth as efficient, reliable, end-to-end logistics provider in Southeast Asia After selling its loss-making shipyard and shipbuilding business in May 2017 to another subsidiary owned by its parent, Mainboard-listed Cosco Shipping International (Singapore) entered the logistics sector 10 months later when it completed the acquisition of established logistics provider Cogent Holdings in March 2018. “Through M&A, we could quickly obtain resources such as warehouses, but ...
View source ↗ - News (RSS)seekingalpha·87d ago·Neutral
Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat
View source ↗ - Newsseekingalpha.com·87d ago·Neutral
Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat Cogent Biosciences is positioned to commercialize bezuclastinib across three indications, leveraging a single precision molecule for multi-market entry. Positive pivotal data in GIST, NonAdvSM, and AdvSM underpin three NDAs, with regulatory decisions expected between late 2026 and early 2027. COGT's commercial infrastructure and $865.9M liquidity provide a runway through 2028, supporting launch and early commercialization activities.
View source ↗ - Newszacks.com·101d ago·Neutral
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Cogent Biosciences (COGT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
View source ↗ - News (RSS)seekingalpha·104d ago·Neutral
Cogent Biosciences reports Q2 results
View source ↗
Earnings
Tue, Feb 16(in 3 months)
Consensus estimate $-0.63 per share
Typical surprise +1.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.59 vs $-0.56miss
- Mon, Aug 10$-0.52 vs $-0.55beat
- Tue, May 5$-0.53 vs $-0.53beat
- Tue, Feb 17$-0.55 vs $-0.51miss
- Fri, Nov 7$-0.50 vs $-0.54beat
- Tue, Aug 5$-0.53 vs $-0.55beat
Estimates and results for COGT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by COGT officers and directors.
- Bought
- $34.9m
- Sold
- $383.9m
3 trades
8 trades
- Morris Arlenesold
- Morris Arlenesold
- Fairmount Funds Management Llcsold
- Fairmount Funds Management Llcsold
- Kearns Evansold
- Green John L.sold
- Sachs Jessicasold
- Robinson John Edwardsold
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Jan 20, 2023 (39d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
